blog image

Managing Methadone and Buprenorphine Use in Pregnancy

December 09, 20212 min read

On Cracking Addiction this week

Post birth the patient's usual oral methadone dose can be continued in the peripartum and post partum period. There is a theoretical concern in the postpartum period of over-sedation as methadone levels may increase as plasma volume and hepatic clearance normalise post the delivery of the child. Women should be closely monitored during this time period to guard against complications.

There are three approaches to manage this potential problem including: stay on the same dose of Methadone with close monitoring, decrease the Methadone dose by 10-20% or reduce the methadone dose by 20 to 40 percent immediately postpartum and closely monitor and follow up the woman to ensure the patient is not in significant withdrawal.

Most women who undergo buprenorphine maintenance therapy will not experience large dose adjustments during their pregnancies and may continue the same doses after delivery

Breast feeding should be promoted with confidence unless active substance use is occurring or otherwise contraindicated. Breastfeeding may reduce the severity of neonatal withdrawal syndrome in the neonate. With Methadone about 1-3% of maternal dosage will be transferred into the breast milk and with buprenorphine the amount of buprenorphine in breast milk is <1 percent of maternal dose. There is a low oral bioavailability with significant absorption unlikely.

Neonatal abstinence syndrome (NAS) is a phenomena when the infant withdraws from drugs that they have been exposed to in utero. NAS is not unique to opioids and can occur with benzodiazepines, nicotine and also SSRI and SNRIs. Methadone causes a withdrawal syndrome in 60–80% of cases with symptoms occurring usually between 48 to 72 hours after birth but also up to five days. In rare circumstances symptoms can be delayed by up to a month. The severity of NAS is not related to the maternal dose of Methadone.

There are lower rate of NAS with buprenorphine compared to methadone which is thought to be secondary to: lower bioavailability, lower transplacental passage and partial agonism. The risk of NAS with buprenorphine is also not dose dependent. However overall the risks of opioid withdrawal during pregnancy are greater to the foetus than those of NAS to the infant so it is important to adequately treat the pregnant woman with opioid use disorder rather than be concerned about the risks of NAS.

Methadone and pregnancyBuprenorphine maintenance therapyNeonatal abstinence syndromeBreastfeeding and opioid usePeripartum methadone dose
blog author image

Dr Thileepan Naren

Dr. Thileepan Naren, an esteemed medical professional, holds prestigious qualifications including MBBS, FACRRM, FRACGP, and FAChAM, showcasing his extensive expertise in the field. Renowned as an Addiction Medicine Specialist, he brings a wealth of experience to the forefront, particularly in catering to the needs of disadvantaged and marginalised communities. With a proven track record, Dr. Naren exemplifies dedication and compassion in providing comprehensive healthcare solutions to those in need.

Back to Blog